Biogen’s Salanersen SMA Treatment Shows Promise After Gene Therapy
Updated: Oct 5
Biogen’s experimental drug, Salanersen, is showing promising potential for treating children with spinal muscular atrophy (SMA), even after they’ve received other gene therapies like Zolgensma. Unlike Spinraza, which requires multiple spinal taps, Salanersen could become a more convenient, once-a-year treatment. In early trials, the drug has demonstrated substantial slowing of neurodegeneration and helped children achieve key developmental milestones, such as sitting unsupported, crawling, and standing—milestones that were previously out of reach for these patients.
In the first phase of testing, children between 6 months and 12 years old received Salanersen at least six months after being treated with Novartis' Zolgensma. After a year, all the patients showed significant improvements.
Neurofilament levels, which are markers of nerve damage, were reduced by 70% after just six months of treatment, suggesting that Salanersen could not only slow disease progression but also improve physical function over time.
Given these results, Biogen is advancing Salanersen directly to Phase 3 trials, bypassing midstage testing. This decision highlights the company's confidence in the drug's potential to make a meaningful difference for children with SMA. The upcoming Phase 3 trials will explore the drug’s effectiveness in both previously treated and untreated patients, which could broaden its impact and further demonstrate its benefits.
Despite challenges in the stock market and stiff competition in the gene therapy space, Salanersen represents a breakthrough for SMA treatment. If successful, it could provide significant relief for families dealing with this devastating condition, offering hope for improved quality of life and better treatment options in the future.
As Biogen moves forward with Phase 3 testing, Salanersen stands out as a beacon of hope for SMA patients. If it continues to show promising results, it could change the landscape of SMA treatment, offering children and their families a much-needed alternative to current therapies.
Created: June 26th, 2025
Citations:
Gatlin, A. (2025, June 25). Can Biogen save even more kids with this new drug? Investor's Business Daily. https://www.investors.com/news/technology/biogen-next-generation-spinraza-spinal-muscular-atrophy-treatment/?utm_source=chatgpt.com
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
Comments